A randomized double-blind parallel-group multicenter study of secukinumab to compare 300 mg and 150 mg at Week 52 in patients with Ankylosing Spondylitis who are randomized to dose escalation after not achieving inactive disease during an initial 1

Brief description of study

People with ankylosing spondylitis (AS) have reduced movement of the spine as well as significant pain in the lower back, buttocks, and often in other joints in the body. The purpose of the study is to determine the safety and benefit of taking secukinumab 300mg, compared to 150mg, in patients with active ankylosing spondylitis. This study will also look to see if treatment with secukinumab has an impact on daily activity (i.e. movement) and quality of sleep.


Clinical Study Identifier: s18-01066
ClinicalTrials.gov Identifier: NCT03350815
Principal Investigator: Fardina Malik.


If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.